1. Efficacy and tolerability of fourteen-day sequential quadruple regimen
- Author
-
Mansour-Ghanaei, Fariborz, Samadi, Alireza, Joukar, Farahnaz, Tirgar Fakheri, Hafez, Hassanipour, Soheil, Ashoobi, Mohammad Taghi, Soltanipour, Soheil, Alizadeh, Ahmad, Rezamand, Gholamreza, and Fathalipour, Mohammad
- Subjects
Helicobacter pylori ,Adverse effects ,Sequential therapy ,Furazolidone ,Eradication - Abstract
The optimal pharmacological regimen for eradication of Helicobacter pylori (H. pylori) has been investigated for many years. This study aimed to evaluate the efficacy and tolerability of bismuth-based quadruple therapy (B-QT) and a modified sequential therapy (ST) regimens in eradication of H. pylori. A randomized, double-blind trial was conducted on 344 patients. Patients with H. pylori infection and without a history of previous treatment were randomized to receive 14-day B-QT (bismuth subcitrate 240 mg, pantoprazole 40 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily) or 14-day ST (bismuth subcitrate 240 mg, pantoprazole 40 mg, amoxicillin 1000 mg, and metronidazole 500 mg twice a day for seven days followed by bismuth subcitrate 240 mg, pantoprazole 40 mg, amoxicillin 1000 mg, and furazolidone 100 mg twice a day for additional seven days). Drug adverse effects were assessed during the study. H. pylori eradication was determined eight weeks after the end of treatment using 14C-urea breath test. Based on per-protocol and intention-to-treat, the eradication rate was significantly higher (p, EXCLI Journal;Vol. 18 2019
- Published
- 2019
- Full Text
- View/download PDF